Patent ID: 7416726
Filing Date: 2008-08-26
Classification: A61K,A61P,C07K,Y02A

Abstract:
1. A method of enhancing cytotoxicity elicited by a therapeutic antibody in a subject, which method comprises disrupting activation of SHIP by Fc-gamma-receptor IIB (FcγRIIB) caused by binding of the antibody to FcγRIIB, wherein the disrupting is accomplished by modifying the Fc region of the antibody to reduce its affinity for FcγRIIB, thereby inhibiting binding of the antibody to FcγRIIB in the subject, wherein the Fc region of the antibody is at least 80% homologous with a native Fc region, and wherein said therapeutic antibody binds activating Fc-receptors with at least the same affinity as the wildtype antibody.